Target intelligence / Profile preview

Mediator complex subunit 4 (MED4)

Target
MED4
Molecular classification
Transcription coactivator, Mediator complex subunit, Nuclear receptor coactivator
01

Overview

Mediator complex subunit 4 (MED4) is a protein component of the multiprotein Mediator complex, which functions as a transcriptional coactivator essential for the regulated transcription of virtually all RNA polymerase II-dependent genes. MED4 acts as a bridge linking gene-specific regulatory transcription factors to the basal transcription machinery, facilitating assembly of the preinitiation complex with RNA polymerase II and general transcription factors. MED4 participates in activation of nuclear receptors, such as the vitamin D receptor, as part of the DRIP (vitamin D receptor-interacting protein) complex. In cancer biology, particularly retinoblastoma, MED4 is essential for cell survival when both RB1 alleles are inactivated, making it a synthetic lethal partner and a potential therapeutic vulnerability in tumors lacking RB1. Alternative splicing results in multiple isoforms of MED4.

Other names
TRAP36VDRIPHSPC126ARC36DRIP36Activator-recruited cofactor 36 kDa componentVitamin D3 receptor-interacting protein complex 36 kDa componentTRAP/SMCC/PC2 subunit p36 subunitFLJ10956RP11-90M2.2
02

Mechanism of action

Not applicable for direct drug targeting; if therapeutically targeted, synthetic lethality in RB1-null environments could be harnessed

03

Biological functions

Regulation of transcription by RNA polymerase IIScaffold for transcriptional preinitiation complex assemblyNuclear receptor coactivation (including vitamin D receptor)
04

Disease associations

RetinoblastomaEpiphyseal dysplasia, multiple, type 4Cancer (as synthetic lethal target in RB1–/– retinoblastoma)
05

Safety considerations

Potential risk with systemic depletion of essential transcriptional coactivators, possible off-target effects if targeted
06

Interacting drugs

No specific drugs directly targeting MED4 are documented; however, gene expression of MED4 can be altered by drug perturbations in research datasets
07

Biomarkers

Expression status of MED4 may serve as a biomarker in retinoblastoma with RB1 deletion for tumor risk assessment

Beyond the preview

Go deeper on Mediator complex subunit 4 (MED4).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Mediator complex subunit 4 (MED4).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call